Splash Beverage Licenses Global Rights to CannEpil Epilepsy Drug

Beverage Company Enters Cannabinoid Pharma Space

Splash Beverage Group's licensing deal marks the company's first entry into cannabinoid pharmaceuticals, a departure from its core beverage business. The agreement grants Splash exclusive global development, manufacturing, and commercialization rights to CannEpil, an investigational therapeutic currently in preclinical or early-stage clinical development. Argent BioPharma, the UK-based licensor, developed the formulation as a targeted treatment for epilepsy patients who don't respond adequately to conventional anticonvulsant medications.

The deal structure wasn't disclosed. Neither company released financial terms, upfront payments, milestone schedules, or royalty rates tied to the agreement. Splash Beverage trades on the NYSE American under ticker SBEV. Shares closed at $0.43 on July 5, giving the company a market cap under $15 million.

Epilepsy affects approximately 3.4 million people in the United States and 50 million globally, according to the World Health Organization. Roughly one-third of epilepsy patients experience drug-resistant seizures, creating a substantial unmet-need population for novel therapeutics.

CannEpil Formulation and Mechanism

CannEpil is a multi-cannabinoid formulation designed to modulate seizure activity through endocannabinoid system pathways. Argent BioPharma hasn't published peer-reviewed efficacy data or disclosed the specific cannabinoid ratios in the proprietary blend. The investigational drug is formulated for oral administration, though dosing regimens and bioavailability profiles remain undisclosed.

Cannabinoid-based epilepsy treatments gained regulatory traction following the FDA's 2018 approval of Epidiolex, a purified CBD isolate manufactured by Jazz Pharmaceuticals. Epidiolex is indicated for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. It generated $888 million in global sales in 2025. CannEpil's multi-cannabinoid approach differentiates it from single-molecule CBD therapies, though clinical superiority hasn't been demonstrated.

The licensing agreement positions Splash to compete in a cannabinoid epilepsy market projected to exceed $2 billion by 2030, driven by expanding indications and patient access.

Development Timeline and Regulatory Path

Splash Beverage hasn't announced a clinical trial initiation date or disclosed CannEpil's current regulatory status with the FDA or international agencies. The company will need to file an Investigational New Drug application with the FDA before commencing Phase 1 human trials in the United States. That process typically requires 12-18 months of preclinical toxicology studies, manufacturing scale-up, and regulatory document preparation.

If CannEpil enters Phase 1 trials in 2027, the earliest possible FDA approval under an accelerated timeline would be 2031-2032. Epilepsy drugs typically require two pivotal Phase 3 trials demonstrating statistically significant reductions in seizure frequency compared to placebo. The FDA's Epidiolex approval took six years from IND filing to market clearance.

Splash Beverage reported $8.2 million in cash and equivalents as of March 31, 2026, in its most recent quarterly filing. Clinical development costs for a cannabinoid epilepsy drug through Phase 3 typically range from $150 million to $300 million, which means the company will need to secure substantial additional capital through equity raises, partnerships, or non-dilutive grants.

Market Position and Competitive Landscape

Splash Beverage enters a cannabinoid epilepsy field dominated by Jazz Pharmaceuticals' Epidiolex and a pipeline of competing multi-cannabinoid formulations in mid-stage trials. GW Pharmaceuticals, now owned by Jazz, spent 15 years and over $1 billion developing Epidiolex before approval. Smaller biotechs including Zelira Therapeutics, Botanix Pharmaceuticals, and Zynerba Pharmaceuticals are advancing transdermal and oral cannabinoid epilepsy candidates, though none have reached pivotal-trial stages.

Splash Beverage's lack of pharmaceutical development infrastructure presents execution risk. The company has no disclosed neurology clinical team. No FDA-approved manufacturing partners. No prior drug-development experience. Its existing operations focus on beverage brands including Copa Di Vino wine and Tapout sports drinks, generating $12.3 million in revenue for fiscal 2025.

For full background on cannabinoid epilepsy therapeutics and the regulatory pathway for CBD-based drugs, see the CannIntel topic hub on cannabinoid epilepsy treatments.

The next signal: investor presentations or clinical-trial registry filings in Q3 2026 that detail CannEpil's development roadmap and capital-raise strategy.